saglik Bilimleri Univercity Gaziosmanpaşa Training and Research Hospital
Istanbul, 34245, Turkey (Türkiye)
NCT Number: NCT04872244
it was planned to investigate the treatment effect of levonorgestrel releasing intrauterine device in patient with isthmocele who were suffering from postmenstrual spotting bleeding and who had no desire for fertility.
Looking for future studies?
Notify Me30 year–40 year
Female
Interventional
Not applicable
Istanbul, 34245, Turkey (Türkiye)
isthmocele is an acquired diverticulum like defect of myometrium in the anterior isthmic part of uterus due to previous cesarean section incision. It can be defined as thinning of the incised site of uterus smaller than 50 % of its normal thickness. the real incidence is unknown. due to low ability of contractility of the postmenstrual spotting bleeding. Accumulation of blood in the isthmocele induces inflammation within the endometrium and causes pain as well. Furthermore, this inflammation can be an absolute reason for secondary infertility. As a result, accumulation of blood in the isthmocele seems to start up the cascade of morbidities. When understanding the mechanism, preventing blood accumulation seems to prevent symptoms other than infertility. Levonorgestrel releasing intrauterine devices can be a way of thinning the endometrium hence, blood accumulation can be avoided. In the literature, surgical correction of the isthmocele has been studied and medical treatment that was mentioned in the literature was the oral contraceptives and only a preliminary report of very small sample size, discussed the effect of levonorgestrel releasing device . in the light of aforementioned clinical knowledge, we planned to investigate the treatment effect of levonorgestrel releasing intrauterine device in patients with postmenstrual bleeding due to isthmocele who were not willing to have baby. These patients will be called back at 6th, 12th and 18th months after applying levonorgestrel releasing device to the uterus. Gynecological examinations will be done and complainants will be questioned.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
usage of mirena ( levonorgestrel releasing intrauterine device) in isthmocele for postmenstrual spotting and do not have desire for fertility
Other names: levonorgestrel
intrauterine administration
Time frame: 18 months
incidence of vaginal spotting bleeding after normal menstrual bleeding
Time frame: 18 months
incidence of pelvic pain felt by the patient during mensturation
Time frame: 18 months
incidence of pelvic pain regardless of mensturation
Gaziosmanpasa Research and Education Hospital
Other Gov
Results of Intrauterine Levonorgestrel Use for the Patients With Isthmocele Suffering From Postmenstrual Spotting Without Fertility Desire
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06691750
Cesarean Scar Defect, Female Urogenital Diseases
Barcelona, Spain
View Trial DetailsNCT06761495
Isthmocele
Tokat Province, Turkey (Türkiye)
View Trial DetailsNCT04734366
Cesarean Section Complications, Isthmocele
Tokat Province, Turkey (Türkiye)
View Trial DetailsNCT04825821
Cesarean Section Complications, Isthmocele
Genoa, Italy
View Trial Details